Navstel is a drug owned by Alcon Pharmaceuticals Ltd. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 29, 2021. Details of Navstel's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7084130 | Intraocular irrigating solution having improved flow characteristics |
Nov, 2021
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Navstel's patents.
Latest Legal Activities on Navstel's Patents
Given below is the list of recent legal activities going on the following patents of Navstel.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Jan, 2018 | US7084130 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Aug, 2006 | US7084130 |
| Recordation of Patent Grant Mailed Critical | 01 Aug, 2006 | US7084130 |
| Issue Notification Mailed Critical | 12 Jul, 2006 | US7084130 |
| Receipt into Pubs | 19 Jun, 2006 | US7084130 |
| Application Is Considered Ready for Issue Critical | 12 Jun, 2006 | US7084130 |
| Dispatch to FDC | 12 Jun, 2006 | US7084130 |
| Receipt into Pubs | 24 May, 2006 | US7084130 |
| Mail Miscellaneous Communication to Applicant | 27 Mar, 2006 | US7084130 |
| Miscellaneous Communication to Applicant - No Action Count | 24 Mar, 2006 | US7084130 |
FDA has granted several exclusivities to Navstel. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Navstel, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Navstel.
Exclusivity Information
Navstel holds 1 exclusivities. All of its exclusivities have expired in 2011. Details of Navstel's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2011 |
US patents provide insights into the exclusivity only within the United States, but Navstel is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Navstel's family patents as well as insights into ongoing legal events on those patents.
Navstel's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Navstel's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 29, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Navstel Generics:
There are no approved generic versions for Navstel as of now.
About Navstel
Navstel is a drug owned by Alcon Pharmaceuticals Ltd. It is used for irrigating the eye during surgical procedures. Navstel uses Calcium Chloride; Dextrose; Magnesium Chloride; Oxiglutatione; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride; Sodium Phosphate as an active ingredient. Navstel was launched by Alcon Pharms Ltd in 2008.
Approval Date:
Navstel was approved by FDA for market use on 24 July, 2008.
Active Ingredient:
Navstel uses Calcium Chloride; Dextrose; Magnesium Chloride; Oxiglutatione; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride; Sodium Phosphate as the active ingredient. Check out other Drugs and Companies using Calcium Chloride; Dextrose; Magnesium Chloride; Oxiglutatione; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride; Sodium Phosphate ingredient
Treatment:
Navstel is used for irrigating the eye during surgical procedures.
Dosage:
Navstel is available in solution form for irrigation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML | SOLUTION | Discontinued | IRRIGATION |